^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.
Published date:
05/13/2020
Excerpt:
RC48-ADC demonstrated a clinically meaningful response and survival benefit in the heavily treated patients with HER2-overexpressing gastric or gastro-esophageal junction cancers.
DOI:
10.1200/JCO.2020.38.15_suppl.4560
Trial ID:
